Bio-Techne Corp

TECH

$67.52

-5.1% last 12 months

Ron Baron Holding value: $363 Million Steven Cohen Holding value: $53.3 Million Chuck Royce Holding value: $36.8 Million Ken Griffin Holding value: $7.16 Million Jim Simons Holding value: $5.39 Million Jefferies Group Holding value: $1.45 Million Ray Dalio Holding value: $809 Thousand Sands Capital Holding value: $511 Thousand Jeremy Grantham Holding value: $0 Joel Greenblatt Holding value: $0 Cathie Wood Holding value: $0 George Soros Holding value: $0

Market Cap

$11.1 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$67.66 - $90.36

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

38.8x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.32 (0.46%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $11.1 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $11.2 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.32 (0.46%)
1 Year Return Profit or loss of share price change plus dividend yield. -4.7%
52-Week High Highest share price in the last 52 weeks. $90.36
52-Week Low Lowest share price in the last 52 weeks. $67.66
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 1.06
Outstanding Shares The number of shares the company has issued and are held by stockholders. 158 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 846 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 38.8
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 170.79
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $1.76
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 9.65
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 5.63
Enterprise Value to Revenue Enterprise value divided by revenue 9.86
Enterprise Value to EBIT Enterprise Value divided by EBIT 37.64
Total Debt to Enterprise Value Total debt divided by enterprise value 0.03
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.18

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $1.14 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $770 Million
EBIT Earnings before tax and interest payments. $298 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $285 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 25.09%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +22.7%
Return on Equity Equity divided by market cap. 14.50%
Return on Assets Indicates a company's profitability in relation to its total assets. 10.81%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 11.86%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q4 2022 Q1 2023 Q2 2023 Q3 2023

About Bio-Techne Corp

CEO: Charles Kummeth

Employees: 2,100

Industry: Biological Product (except Diagnostic) Manufacturing

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems , Novus Biologicals, Tocris Bioscience, ProteinSimple, Exosome Diagnostics, BiosPacific, Cliniqa, Advanced Cell Diagnostics, RNA Medical, Bionostics and BostonBiochem. The company's products are used in both clinical and research contexts. The company was co-founded as a "hematology controls developer" by Dr. Roger C. Lucas, who presently serves as its Chief Scientific Advisor. Bio-Techne is listed on the NASDAQ under the ticker symbol TECH. Writing for Forbes from an investor's perspective, John Reese praised the management team saying it "...appears to be doing a solid job...", a sentiment echoed by Philip van Doorn, writing for Dow Jones MarketWatch. Interviewing investor Edward B. White for the New York Times, Carole Gould noted that White thought the chief executive, Thomas Oland, was a "deeply committed scientist."

Similar stocks

Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc. - Class A
Bio-Rad Laboratories Inc. - Class A
Becton Dickinson & Co.
Becton Dickinson & Co.
Danaher Corp.
Danaher Corp.
Qiagen NV
Qiagen NV
General Electric Co.
General Electric Co.
Enzo Biochem, Inc.
Enzo Biochem, Inc.

News

Cizzle and Bio-Techne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple Western™ Platform | TECH Stock News

Cizzle and Bio-Techne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple Western™ Platform | TECH Stock News

LONDON and MINNEAPOLIS, Sept. 19, 2023/ PRNewswire/-- Bio-Techne Corporation and Cizzle Biotechnology Holdings plc, the UK-

Stock Titan Stock Titan, 9 days ago
Bio-Techne Co. (NASDAQ:TECH) Receives $101.78 Average Price Target from Analysts

Bio-Techne Co. (NASDAQ:TECH) Receives $101.78 Average Price Target from Analysts

… firms recently issued reports on TECH . StockNews.com upgraded shares of … Our Latest Stock Report on TECH Insider Activity Want More Great … Bio-Techne St...

EIN News Tech EIN News Tech, 14 days ago
Mirabella Financial Services LLP Takes $1.29 Million Position in Bio-Techne Co. (NASDAQ:TECH)

Mirabella Financial Services LLP Takes $1.29 Million Position in Bio-Techne Co. (NASDAQ:TECH)

… of Bio-Techne Co. (NASDAQ: TECH – Free Report) during the … Several brokerages have commented on TECH . StockNews.com raised shares of … Our Latest Stock R...

EIN News Tech EIN News Tech, 24 days ago
Unveiling Bio-Techne (TECH)''s Value: Is It Really Priced Right? A Comprehensive Guide

Unveiling Bio-Techne (TECH)''s Value: Is It Really Priced Right? A Comprehensive Guide

Unveiling Bio-Techne (TECH)''s Value: Is It Really Priced Right? A Comprehensive Guide

GuruFocus GuruFocus, about 1 month ago
Never miss a trade
To improve your user experience we use cookies.